Recognized for his industry insight, Alora Pharmaceuticals CEO Art Deas was recently featured in PharmaVoice in the article, “Why a treatment older than the FDA is getting new regulatory scrutiny.”
In the piece, Deas shares insights on the U.S. Food and Drug Administration’s (FDA) evolving approach to desiccated thyroid extract (DTE) products and how Acella Pharmaceuticals, part of the Alora Pharma family, is working to ensure continued patient access, safety, and trust.
Deas notes that Acella’s commitment to clinical research — including an ongoing Phase 3 trial of DTE — aligns with the FDA’s goals of modernizing review standards for long-standing therapies.
“Our focus has always been on delivering consistent, high-quality thyroid medications that patients and providers can rely on,” said Deas. “We welcome the FDA’s clarity and believe it will ultimately strengthen confidence in treatment options for hypothyroidism.”
Read the full article in PharmaVoice.
---
Related Resources: Patients Are Asking
As the FDA updates its guidance on DTE, many patients have questions about what this means for their treatment. Here are some helpful resources:
• Why is the FDA reviewing DTE now? Learn about the FDA’s actions addressing unapproved thyroid medications.
• Will my current Acella medication be affected? Read about the next steps for patients using Acella DTE formulations.
• How is Acella Pharmaceuticals responding? View the latest update related to Acella’s DTE clinical trial.
---
About Alora Pharma
Alora Pharmaceuticals, LLC is a leading specialty pharmaceutical company dedicated to improving patient outcomes through trusted, accessible, and quality medications. Our family of companies, including Acella Pharmaceuticals, develops, manufactures, and markets treatments across multiple therapeutic areas.
Alora is the parent company of six specialty pharmaceutical and pharmaceutical manufacturing companies with manufacturing facilities in Texas and Georgia. Headquartered in Alpharetta, GA, Alora is the parent company of the following organizations that comprise the Alora Family of Companies: Avion Pharmaceuticals, Acella Pharmaceuticals, Osmotica Pharmaceuticals, Sovereign Pharmaceuticals, Trigen Laboratories, Neuvosyn Laboratories, and Vertical Pharmaceuticals.
For media inquiries, please contact: [email protected]